替卡格雷
氯吡格雷
医学
血栓弹性成像
急性冠脉综合征
不利影响
维持剂量
血小板
内科学
阿司匹林
装载剂量
药理学
心脏病学
麻醉
心肌梗塞
作者
Guang Zhong Liu,Song Zhang,Dang Hui Sun,Jing Shi,Wan Lan Bo,Wen Nan Wang,Chong Yang Zhang,Zhong Hua Wang,Wang Feng,Mei He,Yuan Yuan Liu,Shuang Li,Lin Qun Zheng,Yue Li
标识
DOI:10.1007/s00228-019-02687-0
摘要
High on-treatment platelet reactivity (HTPR) after clopidogrel administration in patients with acute coronary syndrome (ACS) has been associated with an increased risk of adverse events. Our previous studies reported that half-dose ticagrelor provides a similar inhibitory effect on adenosine diphosphate (ADP)–induced platelet aggregation as standard-dose ticagrelor, but half-dose of ticagrelor has not been studied in Chinese ACS patients with HTPR. This study aimed to compare the antiplatelet action of half-dose ticagrelor with high-dose clopidogrel in ACS patients with HTPR. In this single-center randomized controlled trial, 80 (of 418 screened, 19.13%) ACS patients with HTPR while on clopidogrel were randomized to either half-dose ticagrelor (90 mg LD, then 45 mg twice daily) or high-dose clopidogrel (150 mg once daily). Platelet function was assessed by thromboelastography (TEG) and light transmission aggregometry (LTA), and adverse events were monitored throughout the study for 30 days. The ADP-induced platelet inhibition rate (IR) as measured by TEG was significantly higher for half-dose ticagrelor compared with high-dose clopidogrel (70.40% [61.10%–91.70%] vs. 44.25% [34.67%–79.07%], p = 0.001). The repeated HTPR rate was dramatically higher for high-dose clopidogrel compared with half-dose ticagrelor (6 of 32, 18.75% vs. 1 of 35, 2.85%; p = 0.04). No patients in either treatment group exhibited a major bleeding event or other adverse events. In ACS patients with HTPR, half-dose ticagrelor is more effective than high-dose clopidogrel in reducing platelet reactivity (NCT03062462).
科研通智能强力驱动
Strongly Powered by AbleSci AI